SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life Sciences reports Profit after tax of Rs -85.09 Mln, in the March 2021 quarter

04 May 2021 Evaluate
The Sales for the quarter ended March 2021 of Rs. 15.57 million declined by -82.02% from Rs. 86.60 millions.The Net Loss for the quarter ended March 2021 is Rs. -85.09 millions as compared to Net Loss of Rs. -25.64 millions of corresponding quarter ended March 2020Operating profit Margin for the quarter ended March 2021 slipped to -71.55% as compared to 9.19% of corresponding quarter ended March 2020


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202103 202003 % Var 202103 202003 % Var 202103 202003 % Var
Sales 15.57 86.60 -82.02 134.78 144.15 -6.50 134.78 144.15 -6.50
Other Income 13.23 29.97 -55.86 77.54 140.36 -44.76 77.54 140.36 -44.76
PBIDT -71.55 9.19 -878.56 -227.93 -212.80 7.11 -227.93 -212.80 7.11
Interest 2.42 2.32 4.31 8.15 4.87 67.35 8.15 4.87 67.35
PBDT -73.97 6.87 -1176.71 -236.08 -217.67 8.46 -236.08 -217.67 8.46
Depreciation 10.66 10.52 1.33 43.46 41.69 4.25 43.46 41.69 4.25
PBT -84.63 -3.65 2218.63 -279.54 -259.36 7.78 -279.54 -259.36 7.78
TAX 0.46 21.99 -97.91 -53.23 -121.83 -56.31 -53.23 -121.83 -56.31
Deferred Tax 0.46 2.27 -79.74 -53.23 -141.55 -62.39 -53.23 -141.55 -62.39
PAT -85.09 -25.64 231.86 -226.31 -137.53 64.55 -226.31 -137.53 64.55
Equity 127.28 127.28 0.00 127.28 127.28 0.00 127.28 127.28 0.00
PBIDTM(%) -459.54 10.61 -4430.36 -169.11 -147.62 14.56 -169.11 -147.62 14.56

Suven Life Sciences Share Price

195.90 -0.10 (-0.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×